• About us
• Contact

Advertisement

Organisation › Details

Alkahest Inc.

Alkahest was established in 2014 by Drs. Tony Wyss-Coray and Karoly Nikolich to further develop and commercialize the pioneering work of Dr. Wyss-Coray, and other leading scientists at Stanford University who demonstrated that factors in the blood of young animals were able to restore mental capabilities in old animals. In their study published online May 4, 2014 in Nature Medicine the scientists characterized important molecular, neuroanatomical and neurophysiological changes in the brains of old mice that shared the blood of young mice. Alkahest is now conducting clinical studies to determine if this promising data in animals can be translated to humans. In addition to Grifols, Alkahest's investors include Bioville Investment Limited, Full House Investment Limited and Stanford University. *

 

	Start	2014-01-01 established (s-off)
	Group	Grifols (Group)
	Predecessor	Stanford University
	Industry	blood plasma
	Region	Redwood City, CA
	Country	United States (USA)
	Street	125 Shoreway Road Suited D
	City	94070 San Carlos, CA
	Tel	+1-650-801-0474
		Address record changed: 2021-12-06
Basic data	Employees	n. a.
		* Document for »About Section«:
		Record changed: 2023-07-10

Advertisement

More documents for Grifols (Group)

• [1] Biotest AG. (4/25/22). "Press Release: Grifols Acquires Majority of Voting Rights in Biotest". Dreieich....
• [2] Grifols S.A.. (9/17/21). "Press Release: Grifols Acquires Tiancheng Pharmaceutical Holdings, the Largest Shareholder of Biotest, to Increase Patients’ Access to Plasma Therapies". Barcelona....
• [3] Grifols S.A.. (11/24/20). "Press Release: Strategic Alliance between Grifols and the Egyptian Government to Boost Plasma-derived Medicines Self-sufficiency in the Middle East and Africa". Barcelona....
• [4] Grifols S.A.. (9/7/20). "Press Release: Grifols to Acquire Alkahest to Enhance Discovery Research and Development". Barcelona & San Carlos, CA....
• [5] Grifols S.A.. (2/18/20). "Press Release: Grifols and the Public Investment Fund of Saudi Arabia Taking Steps to Boost Plasma Medicines Self-supply in the Region". Barcelona....
• [6] Grifols S.A.. (11/13/19). "Press Release: Grifols and Shanghai RAAS Obtain Authorization for Their Strategic Alliance in China". Barcelona....
• [7] Grifols S.A.. (7/31/19). "Press Release: Grifols Increases Its Revenues by 14.3% to EUR 2,423 million, Driven by Its Strategic Growth Plan". Barcelona....
• [8] Grifols S.A.. (2/7/19). "Press Release: Grifols Receives FDA Approval for Procleix Babesia Assay for Donor Screening on Procleix Panther System". Barcelona....
• [9] Grifols S.A.. (1/23/19). "Press Release: Grifols Announces Collaboration and License Agreement with Rigel Pharmaceuticals to Commercialize Fostamatinib in Europe". Barcelona....
• [10] European Invesmtent Bank (EIB). (9/7/18). "Press Release: Investment Plan for Europe – the EIB and Grifols Sign a New Loan Agreement to Advance Research on Rare and Chronic Diseases"....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2024. Made in Germany.